Notably, existing evidence suggested that STING agonist‐based monotherapy modulates the expression of key adaptive immune checkpoint molecules, including PD1 and CTLA‐4 on T cells as well as PD‐L1 on tumor cells and immune cells like macrophages and DCs within the TME. The gene discussed is STING1; the disease is neoplasm.